Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast ...

The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma ...

The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s ...

A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for ...

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an ...

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But ...

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve ...